Baxter drug test shows promise

DEERFIELD -- Baxter International Inc. announced Friday it will begin a larger trial later this year of Gammagard, an intravenous treatment for immune disorders that may help improve cognitive function in patients with mild to moderate Alzheimer's disease. In an initial study, 16 patients treated with Gammagard fared better after six months in tests that measured their cognitive function than eight other patients who were treated with placebos, the company said in a statement Friday.